Articles tagged with Gene Editing
Scientists report that prime editing successfully shuts down a gene involved in smooth muscle cell differentiation, correcting genetic problems and disease models. Prime editing is less complicated and more precise than traditional CRISPR, with fewer components and no collateral damage.
Scientists at MLU and IPB improve CRISPR/Cas9 to simultaneously knockout multiple genes in plants, overcoming previous limitations and enabling complex trait investigations. This approach allows for the study of gene interactions and redundancies, paving the way for more efficient research methods.
Scientists at the University of Queensland are using gene editing technologies to develop crops that can thrive in extreme and variable climate conditions. By integrating CRISPR-Cas9 genome editing into modern breeding programs, researchers aim to increase crop resilience and nutritional quality, ensuring global food security.
A new tool, DECODR, scans for potential errors in CRISPR gene repair, revealing risks to patients. The affordable app uses open-source software and can detect a wide range of DNA mutations at a fraction of the cost.
New gene editing strategies, including CRISPR technologies, are being investigated for treating inherited retinal diseases. Researchers aim to identify the most viable therapeutic approaches using human retinal tissue and organoids.
A newly engineered CRISPR variant called SpRY enables targeted mutation of nearly any genomic sequence in plants, expanding genome editing capabilities and opening up new possibilities for crop improvement. This breakthrough discovery is a significant advancement in the field of plant genome editing.
New gene editing strategies, including CRISPR technologies, are being investigated for treating inherited retinal diseases. The article highlights the most viable therapeutic approaches and discusses safety concerns and challenges in extending the capabilities of CRISPR-Cas9.
Researchers have developed a method to detect Cas9 protein, a key component of CRISPR/Cas gene editing technology, in human plasma and mouse models. This breakthrough aims to identify athletes who may be using gene doping to gain an unfair advantage.
A promising fix to CRISPR-Cas9's problem with unwanted genetic changes has been found using a method that turns off gene-editing until it reaches key cell cycle phases where more accurate repairs are likely to happen.
A new CRISPR/Cas9 variant, miCas9, has been developed to improve the efficiency of gene editing while reducing unintended insertions or deletions. This advancement holds promise for advancing gene editing in genetic research and potentially treating diseases.
Scientists at ChristianaCare's Gene Editing Institute are developing a novel gene therapy for inherited blood disorders like sickle cell disease using CRISPR technology. The team aims to identify genetic variations that affect treatment efficacy and create a tailored approach for personalized medicine.
Researchers at North Carolina State University recommend a coalition, CLEAR-GOV, to provide basic information about gene-edited crops for greater transparency. The proposed model would include details on plant species, trait modifications, and downstream uses.
Researchers have successfully applied CRISPR gene editing to influence the levels of beta-glucan in barley grain, with implications for brewing and distilling industries. The study provides insight into key genes responsible for barley grain composition, enabling plant breeders to accelerate breeding and develop new crop varieties.
A new study improves CRISPR gene editing by mutating the Cas9 enzyme to reduce off-target hits. The mutation increases fidelity up to 93-fold, making it a potentially safer strategy for gene therapy.
A new precision gene editor for mitochondrial DNA has been developed, allowing scientists to make targeted changes without the need for CRISPR technology. This breakthrough could enable researchers to study rare diseases and basic mitochondrial biology in animals.
A new machine learning model, BE-Hive, accurately predicts the outcomes of using different base editors to correct genetic mutations. The model discovered new properties and capabilities of base editors, allowing researchers to design novel tools with improved efficiency.
Researchers have developed a fast CRISPR system that reduces cleavage time from hours to seconds, allowing for high-resolution DNA repair studies and single allele-level genetic editing. The technique uses light-sensitive nucleotides to control Cas9's action, enabling precise control over the editing process.
Scientists at ChristianaCare's Gene Editing Institute have developed a new CRISPR advance that can safely target and disable the NRF2 gene linked to a bleak prognosis in lung cancer tumors. This approach aims to improve the efficacy of conventional chemotherapy and radiation treatments while minimizing harm to normal cells.
Researchers have achieved a groundbreaking milestone in treating inherited blindness by using CRISPR gene editing within the human body. The BRILLIANCE clinical trial aims to repair mutations causing Leber congenital amaurosis type 10, a rare form of blindness. This permanent approach avoids passing on genetic changes to offspring.
A hybrid approach combining gene therapy and gene editing successfully treated an experimental model of a rare genetic disease, significantly enhancing survival. The findings could offer hope for children and adults with various inborn errors of metabolism.
A Japanese survey reveals differing perceptions of gene-edited crops among experts and the general public. Experts see benefits, while the public perceives risks despite acknowledging value. The findings shed light on the deficit model's boundaries in science communication.
Researchers at Columbia University Irving Medical Center have developed a new gene editing tool called INTEGRATE, which uses cryo-electron microscopy to capture high-resolution images of the complex in action. The tool appears to work by targeting DNA for accurate insertion of genetic payloads without introducing DNA breaks.
Researchers have developed new methods that leverage growth regulators and gene editing reagents to trigger seedlings with edited genes. These approaches significantly reduce the time needed for gene-edited plant production from months to weeks, making it easier for small labs and companies to utilize.
Researchers at Harvard Medical School have successfully used CRISPR-Cas9 gene editing to disrupt both latent and active herpes virus in human cells. The findings offer a model system for using gene editing in a localized way to disrupt active replication, but the challenge of delivering gene-editing therapy to neurons remains unsolved.
A new study reveals a new tool that can analyze CRISPR edits in just 48 hours, identifying multiple outcomes of the process. The tool detects subtle mutations to DNA near the site of repair, which may have no consequence for patients but are essential to gauge patient risks.
A recent study published in Frontiers in Genetics confirms that CRISPR-Cas9 gene editing technology is highly accurate and minimizes off-target effects. The research, conducted on zebrafish, adds to a growing body of work suggesting that unintended mutations from gene editing are extremely rare.
A team led by biomedical engineer Kam Leong has received a $3.2 million NIH grant to develop efficient, noninvasive gene editing methods for the brain. The goal is to overcome current inefficiencies in delivering CRISPR-based gene editing elements to the brain and treat devastating diseases like Alzheimer's.
Researchers at the University of Iowa have made significant breakthroughs in delivering gene-editing proteins to airway cells without causing harm. The new peptide-based platform shows promise in treating diseases like cystic fibrosis, COPD, and asthma by repairing or modifying disease-causing mutations.
Scientists have quantified the rate of Cas9-caused off-target mutagenesis in mice through whole-genome sequencing, revealing that guide RNA design can significantly reduce unwanted mutations. The study highlights the need for improved precision in gene editing, particularly in therapeutic applications.
The Carnegie Mellon and Yale research team will scale up production of PNAs, improve DNA binding properties, and develop new nanoparticle formulations for enhanced in vivo editing. The goal is to move the technique closer to clinical therapeutic applications.
Researchers have developed a new CRISPR-Cas9 variant that reduces unintended changes in DNA, increasing precision in gene therapy. The SaCas9-HF variant shows high on-target efficiency and nearly undetectable off-target activity, offering a promising alternative for precise genome editing.
Scientists Zach Lippman and Yuval Eshed review past agricultural revolutions, highlighting key genetic mutations and modifications. They propose using CRISPR gene editing to introduce new variations in core hormonal systems, potentially boosting crop productivity and adaptability.
The book explores the social and ethical implications of gene editing on human germline cells, including its impact on relationships between parents and children, health, normalcy, and well-being. Leading thinkers weigh in on the potential risks and benefits of this revolutionary technology.
Scientists successfully edited the genes of albino lizards using CRISPR-Cas9, allowing them to study gene regulation and vision development. The technique, which can be applied to other animals, demonstrates a new approach for manipulating reptile genomes.
The CRISPR Journal has published new articles on iCas9, a tool that enables precise gene editing without DNA breakage. Researchers also developed BEAT, a computational program to quantify base editing outcomes. Additionally, the journal reported on identifying genetic vulnerabilities in cancer cells via CRISPR-Cas9.
Researchers developed a new gene editing system that simultaneously suppresses proteins inhibiting the immune system in lymphoma cells and activates cytotoxic T lymphocytes. The technology, based on improved CRISPR gene editing, shows promise for treating various diseases including cancer, autoimmune, and inflammatory conditions.
A novel lipid nanoparticle delivery system has been developed to deliver CRISPR/Cas9 gene editing tools into liver cells with up to 90% efficiency. This improvement has the potential to overcome technical hurdles for clinical applications, including treatment of hyperlipidemia and various diseases.
A CWRU team will provide regulatory guidelines for non-traditional gene editing experiments, aiming to protect the public while encouraging creativity and innovation. The researchers will explore options such as licensure requirements, experiment reporting, and equipment restrictions.
A new study found that people in the US are wary of using CRISPR-based genetic engineering to achieve wildlife conservation goals. The research, conducted by a University of Central Florida researcher, suggests that the public perceives the risks of gene editing as outweighing the benefits.
Researchers from CSHL discovered a cryptic mutation in tomatoes that had unexpected effects on growth and yield. By understanding the interaction between this mutation and another gene, they found that duplicating the mutated gene restored its function, providing a solution to agricultural production issues.
A commentary by Chinese experts critiques the first reported instance of germline gene editing in humans, arguing that it was misconceived due to outdated assumptions about HIV infection. The authors recommend strict laws and regulations to oversee future human germline editing experiments.
A breakthrough CRISPR gene-editing tool allows for the simultaneous execution of multiple edits in DNA extracted from human cells. This technology, developed by the Gene Editing Institute and licensed to NovellusDx, can rapidly reproduce an individual patient's cancer tumor genetic features and identify driver mutations.
The CRISPR Journal publishes research on gene editing technologies, including base editors that enable precise base substitutions without DNA cleavage. A new method for multiplex site-directed mutagenesis also offers great promise for studying gene function.
Researchers used CRISPR to edit genes in mice, targeting cells that line the airways of the lungs. The study demonstrated promising results for developing new therapies for congenital lung diseases such as cystic fibrosis and surfactant protein deficiency.
Using CRISPR gene editing, researchers have successfully treated lethal lung diseases in mice by introducing genetic changes during fetal development. The study shows promise for developing new therapies for congenital lung diseases, such as surfactant protein deficiency and cystic fibrosis.
A new approach to gene editing has been developed by scientists at UMass Medical School, allowing for the correction of microduplications associated with 143 different diseases. The strategy uses CRISPR/Cas9 and harnesses the homology-directed repair pathway to remove duplicated sequences and restore functional genes.
Researchers have developed a gene editing approach that corrects over 80% of patient cells, targeting the COL7A1 gene mutation responsible for recessive dystrophic epidermolysis bullosa. The technique shows promise for treating this rare disease with high efficiency and safety.
Purdue University researchers have developed a new gene editing technology that can modify DNA anywhere in the genome, potentially treating diseases like cancer and improving crop production. The new protein, Argonaute from Natronobacterium gregoryi, enables precise edits with increased accessibility
Researchers have developed a more precise gene-editing technique to reduce DNA breaks and prevent cancer in stem cells. This breakthrough could improve the safety of CRISPR treatments for inherited blood disorders.
Researchers at Duke University found that a single CRISPR treatment can safely correct genetic disease for over a year, despite immune responses. The study suggests approaches to address potential challenges and potentially deliver the therapy to infants or restrict Cas9 expression.
A research team has identified and overcome a barrier in CRISPR gene editing that may lay the foundation for sustained treatments using the technique. By increasing the quantity of 'flags' in CRISPR, they were able to extend the effectiveness of treatment from three months to 18 months in mice with Duchenne muscular dystrophy.
A new study published in Molecular Therapy Oncolytics found that combining chemotherapy with CRISPR-Cas9 can stop tumor growth and reduce existing tumor volume in both tissue culture and mouse models. The CRISPR application disables the NRF2 gene, which helps lung cancer tumors develop resistance to chemotherapies.
Researchers have developed a deeper understanding of the CRISPR-Cas12a mechanism, enabling fine-tuning of the gene-editing process. By mapping the molecular structure and sequence of events, scientists can optimize the technology to achieve desired effects while minimizing side effects.
A new machine learning predictive tool, FORECasT, enables scientists to predict the exact mutations resulting from CRISPR-Cas9 gene editing, saving time and resources. The tool was developed using a massive dataset of 40,000 DNA sequences and analysis of over 1 billion DNA sequences.
Scientists at Newcastle University have identified a gene editing method to stop kidney damage in patients with Joubert syndrome, a genetic condition causing brain and kidney issues. The 'exon-skipping' technique may lead to personalized therapies for inherited kidney diseases.
A new paper urges creation of a coordinating global body to assure neutral evaluation of gene editing's benefits and risks. The technologies have breathtaking promise but also profound concerns about unintended consequences, requiring careful review and inclusion of local communities.
Researchers have found that CRISPR-Cas9 generates a strong immune response in humans, with T cells reacting to the Cas9 protein in almost all healthy subjects. However, the study also highlights the need for new solutions to prevent dangerous immune reactions, particularly for genetic diseases requiring in vivo modifications.
UCSB researchers have developed a highly efficient genome editing method that offers complete spatiotemporal control, allowing users to target specific cells or regions within the cell. This approach enables precise and transient gene editing with minimal long-term effects on DNA.
New technology enhances CRISPR-Cas9 gene editing efficiency in mosquitoes, allowing for easier manipulation of gene expression in a wide range of species. This breakthrough enables control of vector-borne diseases, elimination of agricultural insect pests, and potentially gene therapy for human and animal health.
Researchers found that Cas12a is a more choosier enzyme than Cas9 due to its binding mechanism, making it less likely to edit the wrong part of the genome. This discovery could lead to improved gene editing in plants and animals with increased safety for human applications.